Cargando…
A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1)–targeted antibodies nivolumab and pembrolizumab have been two of the lead molecules of this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion,...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
W.B. Saunders
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612055/ https://www.ncbi.nlm.nih.gov/pubmed/28923212 http://dx.doi.org/10.1053/j.seminoncol.2017.06.002 |